<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01306461</url>
  </required_header>
  <id_info>
    <org_study_id>201051</org_study_id>
    <nct_id>NCT01306461</nct_id>
  </id_info>
  <brief_title>Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant Administrations</brief_title>
  <official_title>A Phase III, Randomized, Double-masked 6-month Trial to Compare the Efficacy and Safety of the Preservative-free Fixed-dose Combination of Tafluprost and Timolol Eye Drops to Those of Tafluprost and Timolol Eye Drops Given Concomitantly in Patients With Open Angle Glaucoma or Ocular Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Santen Oy</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Santen Oy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and safety of the preservative-free
      fixed-dose combination of tafluprost and timolol (FDC) to concomitant administration of
      tafluprost and timolol.

      This study will enroll patients who have ocular hypertension or glaucoma.

      The study schedule includes seven visits to the study site and three stages:

        -  washout of 5 days to 4 weeks depending on current glaucoma medication (if any)

        -  6-month study treatment period

        -  1-3 weeks post-study period
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the average diurnal intra-ocular pressure (IOP) at 6 months</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in average diurnal IOP at 2 weeks, 6 weeks and 3 months</measure>
    <time_frame>2 weeks, 6 weeks and 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in timewise IOPs</measure>
    <time_frame>2 weeks, 6 weeks, 3 months and 6 months</time_frame>
    <description>Change from baseline in timewise IOPs (at 8:00, 10:00, 16:00) at 2 weeks, 6 weeks, 3 months and 6 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">401</enrollment>
  <condition>Ocular Hypertension</condition>
  <condition>Open-angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>Timolol and Tafluprost</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Concomitant administration of preservative-free timolol and tafluprost eye drops</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fixed Dose Combination of tafluprost and timolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preservative-free Fixed Dose Combination of tafluprost and timolol eye drops</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Timolol and Tafluprost</intervention_name>
    <description>Preservative-free Timolol eye drops administered twice daily concomitantly with preservative-free Tafluprost eye drops administered once daily
Treatment period 6 months</description>
    <arm_group_label>Timolol and Tafluprost</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fixed Dose Combination of tafluprost and timolol</intervention_name>
    <description>Preservative-free Fixed Dose Combination of tafluprost and timolol eye drops administered once daily.
For masking purposes also: vehicle for timolol administered twice daily
Treatment period 6 months</description>
    <arm_group_label>Fixed Dose Combination of tafluprost and timolol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18 years or more

          -  A diagnosis of ocular hypertension or open-angle glaucoma

          -  Meet specific IOP level at visit 1 (screening)and visit 2 (baseline)

          -  Meet specific visual acuity score

          -  Are willing to follow instructions

          -  Have provided a written informed consent

        Exclusion Criteria:

          -  Females who are pregnant, nursing or planning pregnancy

          -  IOP greater than 36 mmHg at any time point at screening or baseline

          -  Diagnosis of angle-closure glaucoma or secondary glaucoma other than capsular or
             pigmentary glaucoma in either eye

          -  Suspected contraindication or hypersensitivity to study medications tafluprost or
             timolol (e.g. asthma, low pulse) or to wash-out medication brinzolamide

          -  Glaucoma filtration surgery or any other ocular surgery (including ocular laser
             procedures) within 6 months prior to Screening

          -  Use of contact lenses at Screening or during the study

          -  Presence of any abnormality or significant illness that could be expected to interfere
             with the patient safety or study parameters

          -  Current participation in another clinical trial within the last 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Auli Ropo, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Santen Oy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Clemens Vass, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University Vienna, Austria</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marieta Kostianeva, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Mulitiprofile Hospital for Active Treatment Sv.Georgi, Bulgaria</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eva Ruzickova, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vseobecna fakultni nemocnice v Praze, Czech Republic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gábor Holló</last_name>
    <role>Principal Investigator</role>
    <affiliation>Semmelweis Egyetem, Hungary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guna Laganovska, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>P. Stradina Clinical University Hospital, Latvia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria L. Ribeiro, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aibili-Associação p/ Investigação Biomédica e Inovação em Luz e Imagem (AIBILI), Portugal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julián García-Feijóo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinico San Carlos, Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2011</study_first_submitted>
  <study_first_submitted_qc>February 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2011</study_first_posted>
  <last_update_submitted>June 7, 2012</last_update_submitted>
  <last_update_submitted_qc>June 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
    <mesh_term>Timolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

